Neurocrine Biosciences (NBIX) Tops Q2 EPS by 44c

Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $1.25, $0.44 better than the analyst estimate of $0.81. Revenue for the quarter came in at $452.7 million versus the consensus estimate of $446.75 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Genco rejects Diana Shipping bid, calls offer below NAV
• Reading (RDI) Tops Q2 EPS by 4c